NCT04965753 2025-03-04
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Foghorn Therapeutics Inc.
Phase 1 Terminated
Clinical Trials
9 trialsNCT05355753 2024-12-17
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
C4 Therapeutics, Inc.
Phase 1 Terminated
NCT03604783 2024-09-19
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1 Terminated
NCT03670069 2024-05-08
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT04176016 2024-02-02
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
OncoTherapy Science, Inc.
Phase 1 Terminated
NCT03399448 2023-06-22
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
University of Pennsylvania
Phase 1 Terminated
NCT02683148 2019-09-09
DHEA in Synovial Sarcoma Patients
Washington University School of Medicine
Phase 1 Terminated
NCT01469975 2017-05-17
SYNFRIZZ
Centre Leon Berard
Phase 1 Terminated
NCT00027911 2013-02-15
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
Columbia University
Phase 1 Terminated